# Chapter 33 Cerebellar Circuits: Biochemistry, Neurotransmitters and Neuromodulators

# Cannabinoids as Modulators in the Cerebellum

Gary J. Stephens

**Abstract** Cannabinoid CB<sub>1</sub> receptors (CB<sub>1</sub>Rs) are the most widespread G-proteincoupled receptors (GPCRs) in the mammalian CNS. CB<sub>1</sub>Rs are present on inhibitory and excitatory presynaptic terminals supplying Purkinje cells (PCs), the sole output of the cerebellar cortex, where CB<sub>1</sub>R activation suppresses transmitter release. CB<sub>1</sub>Rs are part of the endocannabinoid (eCB) system, activated by the lipid mediator 2-arachidonoyl glycerol (2-AG) via retrograde transmission within the cerebellum. CB<sub>1</sub>Rs also mediate synaptic plasticities to modulate cerebellar learning. This review will discuss the latest knowledge regarding CB<sub>1</sub>R circuitry and signalling and their potential modulation.

Keywords CB<sub>1</sub> receptor • Endocannabinoid • Purkinje cells

### **33.1 Introduction**

The release of excitatory glutamate, from parallel fibres (PF) and climbing fibres (CF), and inhibitory GABA, predominantly from basket cell interneurons (INs), onto output PCs, is intimately controlled by  $CB_1Rs$  in the cerebellar cortex (Stephens 2009).  $CB_1Rs$  are activated by eCBs and may be modulated by exogenous synthetic cannabinoids and plant-derived phytocannabinoids (Pertwee et al. 2010; Hill et al. 2012). The major effect of presynaptic  $CB_1R$  activation is suppression of neurotransmitter release (Kano et al. 2009). Cannabinoids also activate  $CB_2$  receptors, expressed predominantly in microglia within the CNS, and potentially GPR55 receptors (Pertwee et al. 2010). However, key known effects of cannabinoids on synaptic function are mediated via presynaptic  $CB_1Rs$  (see Hoffmann and Lupia 2013).

G.J. Stephens (🖂)

School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AJ, UK e-mail: g.j.stephens@reading.ac.uk

<sup>©</sup> Springer International Publishing Switzerland 2016

D.L. Gruol et al. (eds.), *Essentials of Cerebellum and Cerebellar Disorders*, DOI 10.1007/978-3-319-24551-5\_33

#### **33.2** CB<sub>1</sub>R Expression Within the Cerebellum

CB<sub>1</sub>Rs are expressed at presynaptic terminals onto PCs, the principal neurons of the cerebellar cortex, which provide inhibitory innervation of deep cerebellar nuclei. Thus, CB<sub>1</sub>Rs are uniquely positioned to control cerebellar function and, in particular, modulation of fine motor co-ordination. CB<sub>1</sub>Rs are expressed on perisynaptic PF membranes, with lower expression at CF inputs onto dendritic shafts (Kawamura et al. 2006). CB<sub>1</sub>Rs are expressed at higher levels on inhibitory IN presynaptic terminals, predominantly on basket cells, which form specialized 'pinceau' regions surrounding the PC axon initial segment (Rodríguez-Cueto et al. 2014). In the cerebellar cortex, CB<sub>1</sub>Rs are activated preferentially by 2-AG (Szabo et al. 2006), over the other major brain eCB, arachidonylethanolamide (anandamide). The 2-AG biosynthetic enzyme diacylglycerol lipase- $\alpha$  (DAGL $\alpha$ ) is localized to PC somatodendritic regions, with a subcellular distribution at the base of postsynaptic spines (Yoshida et al. 2006). The 2-AG degrading enzyme monoacylglycerol lipase (MGL) is localised to PF terminals (Tanimura et al. 2012). CB<sub>1</sub>R expression has also been reported on microglial and astrocytes within the cerebellar cortex (Rodríguez-Cueto et al. 2014); the role of the CB<sub>1</sub>R at such tripartite synapses will be of clear future interest.

In PC postsynaptic dendritic spines, 2-AG is synthesised by DAGL $\alpha$  from DAG (produced from phosphatidylinositol 4,5-bisphosphate (PIP2) by phospholipase C (PLC)) in turn activated by  $G\alpha_{q/11}$  GPCRs. 2-AG is released retrogradely to act on presynaptic CB<sub>1</sub>Rs at excitatory PF and inhibitory IN terminals to suppress release of glutamate (Glu) or GABA, respectively. Astrocytes and microglial also express CB<sub>1</sub>Rs. CB<sub>1</sub>Rs are predominantly coupled to  $G\alpha_{i/o}$  to inhibit VGCCs (via G $\beta\gamma$ ) and/ or activate K<sup>+</sup> channels (via AC inhibition and subsequent reduction in cAMP). 2-AG is catabolised by MGL produced by PF terminals.

## 33.3 CB<sub>1</sub>R Signalling in the Cerebellum

During retrograde transmission, 2-AG is synthesised *de novo* from diacylglycerol (DAG) by DAGL $\alpha$  and released 'on-demand' from postsynaptic somatodendritic PC regions to act on presynaptic CB<sub>1</sub>Rs (Urbanski et al. 2010; see Fig. 33.1). Release of 2-AG, by not yet fully resolved pathways, is triggered predominantly by increases in postsynaptic Ca<sup>2+</sup> concentration via depolarization-induced opening of voltage-gated Ca<sup>2+</sup> channels (VGCCs) and/or synaptically-driven activation of iono-tropic AMPA receptors and certain G $\alpha_{q/11}$ -coupled GPCRs (Ohno-Shosaku and Kano 2014). Presynaptic CB<sub>1</sub>Rs couple predominantly to G $\alpha_{i/o}$  subunits, which inhibit adenylyl cyclase (AC)-mediated generation of cyclic adenosine monophosphate (cAMP) and liberate G $\beta\gamma$  subunits (Pertwee et al. 2010). CB<sub>1</sub>Rs activation causes pertussis toxin-sensitive inhibition of VGCCs and activation of inwardly rectifier K<sup>+</sup> channels (Guo and Ikeda 2004), CB<sub>1</sub>Rs can also link directly to the vesicular release machinery; these effects are mediated by G $\beta\gamma$  subunits (Stephens 2009).



Fig. 33.1 2-AG is fundamental to cannabinoid signalling in the cerebellar cortex

CB<sub>1</sub>Rs activation by synthetic agonists such as WIN55212-2 (WIN55) and CP55940, inhibits action potential-evoked, and spontaneous, inhibitory postsynaptic currents (IPSCs) at IN-PC synapses or excitatory postsynaptic currents (EPSCs) at PF-PC and CF-PC synapses; CB<sub>1</sub>Rs activation also reduces frequency of 'miniature' IPSCs (mIPSCs) at IN-PC synapses (Takahashi and Linden 2000). CB<sub>1</sub>R antagonists/inverse agonists increase mIPSCs (Ma et al. 2008); such effects are consistent with the presence of a strong, modulatable eCB tone in the cerebellum (Kreitzer et al. 2002).

Release of 2-AG causes short-term or long-term modulation of neurotransmitter release, offering the potential to fine-tune motor learning in the cerebellum. A prominent form of short-term modulation is the suppression of inhibitory GABA release from IN terminals (depolarization-induced suppression of inhibition, DSI) or suppression of excitatory glutamate release (depolarization-induced suppression of excitation, DSE) (Kreitzer and Regehr 2001). A major presynaptic effect in DSE is inhibition of VGCCs (Brown et al. 2004). eCBs also mediate long-term synaptic plasticity, due to repeated stimulation of synaptic inputs, but also in response to prolonged postsynaptic activity, and requiring additional activity to augment CB<sub>1</sub>R effects (Ohno-Shosaku and Kano 2014). Both long-term depression and potentiation are modulated by CB<sub>1</sub>R at PF-PC synapses, the balance of effects is proposed to underlie cerebellar learning (Vogt and Canepari 2010).

#### **33.4** Association of CB<sub>1</sub>Rs with Cerebellar Dysfunction

Disruption of cerebellar circuitry is commonly associated with ataxia, a spectrum of diseases associated with motor co-ordination deficits. Whilst animals lacking  $CB_1R$  have no gross deformities, they have deficits in eyeblink conditioning, suggesting that  $CB_1Rs$  control discrete cerebellar-dependent, motor learning processes

(Kishimoto and Kano 2006). In fact, CB<sub>1</sub>R agonists cause severe motor incoordination and can be used to induce ataxia (Patel and Hillard 2001). We have shown that du<sup>2J</sup> 'ducky' ataxic mouse mutants exhibit irregular PC firing and disrupted CB<sub>1</sub>Rmediated signalling that could contribute to disease phenotype (Wang et al. 2013). In post-mortem spinocerebellar ataxia brain tissue, CB<sub>1</sub>R expression was increased in glial and PCs (Rodríguez-Cueto et al. 2014); therefore, up-regulated CB<sub>1</sub>R could be useful disease marker and/or may serve a neuroprotective function (Stephens 2016).

CB<sub>1</sub>R antagonists/inverse agonists have been shown to increase inhibitory neurotransmission at IN-PC synapses (Ma et al. 2008). Such agents have potential to dampen cerebellar excitability. These agents included rimonabant; however, rimonabant withdrawal as a therapeutic anti-obesity agent, due to fears of increased suicide and depression, has curtailed several related drug development programmes. Potential alternatives are CB<sub>1</sub>R negative allosteric antagonists, such as Org-27569 and PSNCBAM-1 (Ross 2007). These agents, somewhat paradoxically, increase binding of orthosteric ligands, but decrease their efficacy; this occurs in a liganddependent fashion (Baillie et al. 2013). We have shown such 'functional selectivity' for PSNCBAM-1 at IN-PC synapses (Wang et al. 2011). Moreover, unlike CB<sub>1</sub>R antagonists/inverse agonists, PSNCBAM-1 had no intrinsic effects on inhibitory transmission. These studies indicate that negative allosteric antagonists offer potential advantages including reduced side effects and toxicity and present future potential for selective manipulation of the eCB system within the cerebellar cortex.

#### References

- Baillie GL, Horswill JG, Anavi-Goffer S et al (2013) CB<sub>1</sub> receptor allosteric modulators display both agonist and signaling pathway specificity. Mol Pharmacol 83:322–338
- Brown SP, Safo PK, Regehr WG (2004) Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels. J Neurosci 24:5623–5631
- Guo J, Ikeda SR (2004) Endocannabinoids modulate N-type calcium channels and G-proteincoupled inwardly rectifying potassium channels via CB<sub>1</sub> cannabinoid receptors heterologously expressed in mammalian neurons. Mol Pharmacol 65:665–674
- Hill AJ, Williams CM, Whalley BJ, Stephens GJ (2012) Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther 133:79–97
- Hoffman AF, Lupica CR (2013) Synaptic targets of Δ<sup>9</sup>-tetrahydrocannabinol in the central nervous system. Cold Spring Harb Perspect Med 3 pii: a012237.
- Kano M, Ohno-Shosaku T, Hashimotodani Y et al (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89:309–380
- Kawamura Y, Fukaya M, Maejima T et al (2006) CB<sub>1</sub> is the major cannabinoid receptor at excitatory presynaptic site in the hippocampus and cerebellum. J Neurosci 26:2991–3001
- Kishimoto Y, Kano M (2006) Endogenous cannabinoid signaling through the CB<sub>1</sub> receptor is essential for cerebellum-dependent discrete motor learning. J Neurosci 26:8829–8837
- Kreitzer AC, Regehr WG (2001) Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci 21:RC174

- Kreitzer AC, Carter AG, Regehr WG (2002) Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum. Neuron 34:787–796
- Ma YL, Weston SE, Whalley BJ, Stephens GJ (2008) The phytocannabinoid  $\Delta^{9}$ -tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum. Br J Pharmacol 154:204–215
- Ohno-Shosaku T, Kano M (2014) Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol 29:1–8
- Patel S, Hillard CJ (2001) Cannabinoid CB<sub>1</sub> receptor agonists produce cerebellar dysfunction in mice. J Pharmacol Exp Ther 297:629–637
- Pertwee RG, Howlett AC, Abood ME et al (2010) International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB<sub>1</sub> and CB<sub>2</sub>. Pharmacol Rev 62:588–631
- Rodríguez-Cueto C, Benito C, Fernández-Ruiz J et al (2014) Changes in CB1 and CB2 receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias. Br J Pharmacol 171:1472–1489
- Ross RA (2007) Allosterism and cannabinoid  $CB_1$  receptors: the shape of things to come. Trends Pharmacol Sci 11:567–572
- Stephens GJ (2009) G-protein-coupled-receptor-mediated presynaptic inhibition in the cerebellum. Trends Pharmacol Sci 8:421–430
- Stephens GJ (2016) Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia? J Physiol [Epub ahead of print Mar 11]
- Szabo B, Urbanski MJ, Bisogno T et al (2006) Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. J Physiol 577:263–280
- Takahashi KA, Linden DJ (2000) Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. J Neurophysiol 83:1167–1180
- Tanimura A, Uchigashima M, Yamazaki M et al (2012) Synapse type-independent degradation of the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression. Proc Natl Acad Sci U S A 109:12195–12200
- Urbanski MJ, Kovacs FE, Szabo B (2010) Endocannabinoid-mediated synaptically evoked suppression of GABAergic transmission in the cerebellar cortex. Neuroscience 169:1268–1278
- Vogt KE, Canepari M (2010) On the induction of postsynaptic granule cell-Purkinje neuron LTP and LTD. Cerebellum 9:284–290
- Wang X, Horswill JG, Whalley BJ, Stephens GJ (2011) Effects of the allosteric antagonist 1-(4-chlorophenyl)-3-[3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl]urea (PSNCBAM-1) on CB1 receptor modulation in the cerebellum. Mol Pharmacol 79:758–767
- Wang X, Whalley BJ, Stephens GJ (2013) The du<sup>2J</sup> mouse model of ataxia and absence epilepsy has deficient cannabinoid CB<sub>1</sub> receptor-mediated signalling. J Physiol 591:3919–3933
- Yoshida T, Fukaya M, Uchigashima M et al (2006) Localization of diacylglycerol lipase-alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2-arachidonoyl-glycerol, and presynaptic cannabinoid CB<sub>1</sub> receptor. J Neurosci 26:4740–4751